Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.
Read the notice.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer